[Webmaster's clarification: for citations 1-10 see Cancer Legal Citations]

11. Abrams, Donald I., et al [2003]. Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection: A Randomized, Placebo-Controlled Clinical Trial. Ann Intern Med. 2003 Aug 19;139(4):258-66.5. Dixon WE. The pharmacology of Cannabis indica. BMJ 1899; ii: 1354-1357.

12. Petro DJ, et al., "Treatment of Human Spasticity with Delta-9- Tetrahydrocannabinol," Journal of Clinical Pharmacology 21 (1981): 413-416. http://www.druglibrary.org/schaffer/hemp/medical/spast1.htm

13. Petro DJ. "Marihuana as a therapeutic agent for muscle spasm and spasticity," Psychosomatics 21 (1980): 81-85.

14. Petro DJ. Cannabis in multiple sclerosis: Women's health concerns. Journal of Cannabis Therapeutics 2002;2(3-4):161-175.

15. Musty RE, Consroe P. Spastic disorders. In: Grotenhermen F, Russo EB, editors. Cannabis and cannabinoids: Pharmacology, toxicology, and therapeutic potential. Binghamton, NY: Haworth Press; 2002. p. 195-204.

16. Clifford D, "Tetrahydrocannabinol for Tremors in Multiple Sclerosis," Annals of Neurology 13 (1983): 669-671.

17. Ungerleider J, et al., "Delat-9-THC in the treatment of Spasticity Associated with Multiple Sclerosis," Advances in Alcohol and Substance Abuse 7 (1988): 39-50.

18. Meinck H, et al., "Effects of cannabinoids on spasticity and ataxia in multiple sclerosis," Journal of Neurology 226 (1989): 120-122. http://www.druglibrary.org/schaffer/hemp/medical/ms1.htm

19. Consroe P, et al., "The Perceived Effects of Smoked Cannabis on Patients with Multiple Sclerosis," European Neurology 38 (1997): 44-48.

20. Growing L, et al., "Therapeutic use of cannabis: clarifying the debate," Drug and Alcohol Review 17 (1998): 445-452.

21. Baker D, et al. "Cannabinoids control spasticity and tremor in a multiple sclerosis model," Nature 404 (2000): 84-87.

22. Page SA, Verhoef MJ, Stebbins RA, Metz LM, Levy JC. Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci 2003; 30:201-205.

23. Killestein J, Polman CH. Cannabis Use in Multiple Sclerosis: Excited Interest. Can. J. Neurol. Sci. 2003; 30: 181-182

24. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation 2003;17:18-26.

25. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; "Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial," Lancet. 2003 Nov 8;362(9395):1517-26.

26. Metz L, Page S. Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use? Lancet 2003;362(9395):1513.

27. A. Achiron, et al. "Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis." Journal of Neuroimmunology 102 (2000): 26-31.

28. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D., "Cannabinoids inhibit neurodegeneration in models of multiple sclerosis," Brain. 2003 Jul 22.

29. Emma Ross, First major study of medicinal marijuana indicates it could help in multiple sclerosis, Associated Press, Thursday, November 6, 2003

30. Beard S, Hunn A, Wight J., "Treatments for spasticity and pain in multiple sclerosis: a systematic review," Health Technol Assess. 2003;7(40):iii, ix-x, 1-111. The report also said: "There is limited evidence of the effectiveness of four oral drugs for spasticity: baclofen, dantrolene, diazepam and tizanidine. Tizanidine appears to be no more effective than comparator drugs such as baclofen and has a slightly different side-effects profile. Despite claims that it causes less muscle weakness, there was very little evidence that tizanidine performed any better in this respect than other drugs, although it is more expensive. The findings of this review are consistent with reviews of the same treatments for spasticity derived from other aetiologies. There is good evidence that both botulinum toxin (BT) and intrathecal baclofen are effective in reducing spasticity, and both are associated with functional benefit. However, they are invasive, and substantially more expensive. None of the studies included in the review of pain were designed specifically to evaluate the alleviation of pain in patients with MS and there was no consistency regarding the use of validated outcome measures. It was suggested that, although expensive, the use of intrathecal baclofen may be associated with significant savings in hospitalisation costs in relation to bed-bound patients who are at risk of developing pressure sores, thus enhancing its cost-effectiveness. No studies of cost-effectiveness were identified in the review of pain. There is evidence, albeit limited, of the clinical effectiveness of baclofen, dantrolene, diazepam, tizanidine, intrathecal baclofen and BT and of the potential cost-effectiveness of intrathecal baclofen in the treatment of spasticity in MS."

All rights reserved. Copyright pending 2008.